The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Jason Hassenstab
Project Title: Psychological Well Being and Momentary Cognition
Date: February 22, 2023
Request ID: S2304
Aim 1: To determine if day to day changes in cognition are related to well-being and whether this relationship can predict AD pathological burden and disease progression.
Aim 2:
Aim 3:
Aim 4:
Investigator: Tammie Benzinger
Project Title: F18 – Fluselenamyl Beta Amyloid PET Imaging for Alzheimer Disease
Date: February 1, 2023
Request ID: S2303
Aim 1: Dosimetry – To assess the dosimetry and safety of F18-Fluselenamyl in healthy adult volunteers (n=8, recruited and scanning)
Aim 2: Proof of Concept: To assess F18-Fluselenamyl sensitivity for imaging Amyloid beta pathophysiology and conduct comparative analysis of PET imaging data using C11-PIB imaging in same participants. (n=36, 18 healthy (9 male and 9 female) with CDR 0 and 18 AD participants(9 M and 9 F) with CDR >=0.5)
Aim 3: Aim 3A: Aim 2 participants will be invited for a short term f/u to undergo repeat F18-Fluselenamyl ~1 month after baseline FSA scan (n=10)
Aim 4: Aim 3B: 18 participants from Aim 2 will have a longitudinal f/u visit ~18 months after the initial study visit to repeat Fluselenamyl, PIB, MRI scan.
Investigator: Brendan Lucey
Project Title: Acute effect of lemborexant on CSF amyloid-beta and tau
Date: January 24, 2023
Request ID: S2302
Aim 1: To test the hypothesis that treatment with lemborexant 25 mg will decrease the CSF pT181/T181 ratio compared to placebo (primary outcome).
Aim 2: Measure the effect of lemborexant on other CSF AD biomarkers such as pS202/S202, pT217/T217, and Aβ (secondary outcomes).
Aim 3:
Aim 4:
Investigator: Andrei Vlassenko and Manu Goyal
Project Title: White Matter Metabolism in the Context of Aging, White Matter Hyperintensities, and Alzheimer’s Disease
Date: January 17, 2023
Request ID: S2301
Aim 1: Determine the quantitative topography of white matter metabolism (including glucose metabolism, oxygen metabolism, cerebral blood flow, and aerobic glycolysis in relation to structural/microstructural brain MRI in healthy young adults and older adults without white matter hyperintensities (WMH).
Aim 2: Determine the quantitative topography of white matter metabolism in cognitively unimpaired older adults with WMH. We will compare these data to those obtained in Aim 1.
Aim 3: Analyze brain MRIs in our existing cohort of adults who have previously undergone metabolic PET imaging.
Aim 4:
Investigator: Ilya E. Monosov
Project Title: High precision within subject reverse engineering of psychiatric disorders
Date: December 24, 2021
Request ID: S2105
Aim 1: High precision rapid online behavioral assay to reverse engineer maladaptive behavior within individual subjects
Aim 2: Uncovering precise behavioral variables that disrupt adaptive decision making and cognition
Aim 3: Relating identified disruptions in adaptive behavior to genetics
Aim 4:
Investigator: ADİL ALPEREN ÇİFTCİ
Project Title: Deciphering Sounds Through Patterns of Vibration on the Skin
Date: November 30, 2021
Request ID: S2104
Aim 1: the aim of representing environmental sounds such that very different sounds feel very different and very similar sounds feel very similar
Aim 2:
Aim 3:
Aim 4:
Investigator: Kevin Yarasheski
Project Title: Blood collection from individuals with APOE2/2, APOE2/3, APOE2/4, APOE3/3, APOE3/4 and APOE4/4 genotype to obtain plasma for the development and analytical validation of a plasma ApoE proteotype test
Date: June 23, 2021
Request ID: S2103
Aim 1: The aim of this study is to collect plasma from individuals with APOE2/2, APOE2/3, APOE2/4, APOE3/3, APOE3/4 and APOE4/4 genotype to develop and analytically validate a plasma ApoE proteotype assay
Aim 2:
Aim 3:
Aim 4:
Investigator: Jeffrey M Zacks
Project Title: Improving everyday memory in healthy aging and early AD
Date: February 11, 2021
Request ID: S2102
Aim 1: Test whether and how attention to event segmentation improves elders� memory for everyday activity at delays from minutes to weeks.
Aim 2: Test the hypothesis that effective event segmentation improves the resolution of elders� posterior/medial memory representations.
Aim 3: Test whether the mechanisms and consequences of segmentation improvement are maintained or impaired by early symptomatic Alzheimer�s disease.
Aim 4:
Investigator: Catherine Roe and Ganesh Babulal
Project Title: Naturalistic driving as a functional neurobehavioral marker of preclinical and symptomatic Alzheimer disease (AD)
Date: January 5, 2021
Request ID: S2101
Aim 1: Use established cerebrospinal fluid (CSF) and imaging biomarkers to define preclinical AD and test the ability of the DRIVES to distinguish persons with and without preclinical AD among cognitively normal older adults, and assess the ability of the system to predict the future onset of dementia.
Aim 2: Test the ability of the DRIVES data to distinguish cognitively normal persons from those with dementia cross-sectionally, and to examine driving behavior over time for both groups.
Aim 3: Determine whether the DRIVES data, combined with cognitive, health, and functional data from older adults, can improve prediction of incident cognitive impairment and dementia.
Aim 4:
Investigator: Sarah Hartz (MPI Jessica Mozersky)
Project Title: WeSHARE (WashU Study of Having AD dementia Research results Explained)
Date: December 9, 2020
Request ID: S2004
Aim 1: Determine impact of returning research results to participants
Aim 2:
Aim 3:
Aim 4: